Andere Sprachen Tempest Therapeutics, Inc.

Aktien

A3CSM8

US87978U1088

TPST

Realtime-Estimate Cboe BZX Andere Börsenplätze 01:59:07 19.06.2024			% 5 Tage	% 1. Jan.
3,97 ^USD	+39,30 %		-8,36 %	-35,23 %

09.05.	Tempest Therapeutics, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
09.04.	Tempest Therapeutics, Inc. berichtet auf der AACR-Jahrestagung neue präklinische Daten für TPST-1120 bei RCC	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat in First-Line Hepatocellular Carcinoma	14:59
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma	00:23
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	07.06.
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)	31.05.
Tempest Therapeutics : Corporate Presentation - June 2024	30.05.
Tempest to Participate in Upcoming Investor Conferences	21.05.
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update	09.05.
Tempest Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	26.04.
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	10.04.
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	09.04.
Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	09.04.
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04.04.
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04.04.
Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04.04.
Tempest Therapeutics : Corporate Presentation - April 2024	29.03.
Tempest Therapeutics : Corporate Presentation - March 2024	22.03.
Tempest Reports Year End 2023 Financial Results and Provides Business Update	20.03.
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
Tempest Reports Year End 2023 Financial Results and Provides Business Update	19.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Tempest Therapeutics, Inc.

Aktien

A3CSM8

US87978U1088

TPST

Andere Sprachen

Filter